BACKGROUND AND PURPOSE: This retrospective study was to evaluate the local control and survival of (125)I brachytherapy for recurrent and/or locally advanced adenoid cystic carcinoma (ACC) of the oral and maxillofacial region. PATIENTS AND METHODS: A total of 38 patients with recurrent and/or locally advanced ACC of the oral and maxillofacial region received (125)I brachytherapy alone from 2001-2010. Twenty-nine were recurrent cases following previous surgery and radiation therapy. The other 9 cases involved primary tumors. Overall, 12 tumors were located in the major salivary glands, 12 in the minor salivary glands, and 14 in the paranasal region, the nasal cavity or the skull base. The prescribed dose was 100-160 Gy. RESULTS: Patients were followed for 12-122 months (median 51 months). The 2-, 5-, and 10-year local tumor control rates were 86.3, 59, and 31.5 %, respectively. The 2-, 5-, and 10-year overall survival rates were 92.1, 65 and 34.1 %, respectively. Tumors > 6 cm had significantly lower local control and survival rates. No severe complications were observed during follow-up. CONCLUSION: (125)I brachytherapy is a feasible and effective modality for the treatment of locally advanced unresectable or recurrent ACC.
BACKGROUND AND PURPOSE: This retrospective study was to evaluate the local control and survival of (125)I brachytherapy for recurrent and/or locally advanced adenoid cystic carcinoma (ACC) of the oral and maxillofacial region. PATIENTS AND METHODS: A total of 38 patients with recurrent and/or locally advanced ACC of the oral and maxillofacial region received (125)I brachytherapy alone from 2001-2010. Twenty-nine were recurrent cases following previous surgery and radiation therapy. The other 9 cases involved primary tumors. Overall, 12 tumors were located in the major salivary glands, 12 in the minor salivary glands, and 14 in the paranasal region, the nasal cavity or the skull base. The prescribed dose was 100-160 Gy. RESULTS:Patients were followed for 12-122 months (median 51 months). The 2-, 5-, and 10-year local tumor control rates were 86.3, 59, and 31.5 %, respectively. The 2-, 5-, and 10-year overall survival rates were 92.1, 65 and 34.1 %, respectively. Tumors > 6 cm had significantly lower local control and survival rates. No severe complications were observed during follow-up. CONCLUSION: (125)I brachytherapy is a feasible and effective modality for the treatment of locally advanced unresectable or recurrent ACC.
Authors: Alexander D Rapidis; Nikolaos Givalos; Hariklia Gakiopoulou; Gregory Faratzis; Spyros D Stavrianos; George A Vilos; Emmanuel E Douzinas; Efstratios Patsouris Journal: Oral Oncol Date: 2005-03 Impact factor: 5.337
Authors: Thomas Mücke; Andrea Tannapfel; Marco R Kesting; Stefan Wagenpfeil; Luisa K Robitzky; Klaus-Dietrich Wolff; Frank Hölzle Journal: Auris Nasus Larynx Date: 2010-02-23 Impact factor: 1.863
Authors: G G Grabenbauer; C Rödel; T Brunner; S Schulze-Mosgau; V Strnad; R G Müller; H Iro; R Sauer Journal: Strahlenther Onkol Date: 2001-07 Impact factor: 3.621
Authors: Yu L Jiang; Na Meng; Jun J Wang; Ping Jiang; Hui Sh Yuan; Chen Liu; Ang Qu; Rui J Yang Journal: Radiat Oncol Date: 2010-07-30 Impact factor: 3.481
Authors: Ming-Hui Mao; Jian-Guo Zhang; Lei Zheng; Hong Gao; Jie Zhang; Shu-ming Liu; Ming-wei Huang; Yan Shi Journal: Strahlenther Onkol Date: 2014-09-09 Impact factor: 3.621